

**AHERKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
Battin Complex, 35, Ganesh Peth,  
Solapur -413 005.  
Ph.No.0217-2622223  
Email:-aherkarandco@gmail.com

---

**INDEPENDENT AUDITOR'S REPORT  
FOR THE YEAR ENDED ON 31<sup>ST</sup> MARCH, 2021.**

Date: 02/09/2021

To the Members of  
**MVL Medisynth Private Limited,**  
SOLAPUR.

**Report on the Audit of the Standalone Financial Statements**

We have audited the accompanying Standalone Financial Statements of MVL Medisynth Private Limited ("the company"), which comprise the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the financial statements, including a summary of Significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Standalone Financial Statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021 its profit including other comprehensive income, its cash flows and the changes in equity for the year ended on that date.

**Basis For Opinion**

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion of the Standalone Financial Statements.

...2...



## Key Audit Matters

### Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Director is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



The Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



- e. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India, in terms of sub-section (11) of section 143 of the Companies Act 2013, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by section 143(3) of the Act, we report that:
  - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - c) The Balance Sheet, the Statement of Profit and Loss, the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
  - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.




- e) On the basis of written representations received from the directors as on March 31, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2021 from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial control over financial reporting of the company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- a) The company has disclosed the impact of pending litigations on its financial position in its financial statements to the financial statements;
- b) The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses.
- c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

DATE: 02/09/2021.

PLACE: SOLAPUR.

FOR AHERKAR & CO.,  
CHARTERED ACCOUNTANTS.  
F.R.No. 100170W

  
( CA S. P. Jawalkar )  
Proprietor.  
M.No. 130176.  
UDIN-21130176AAAAIJ4503



## ANNEXURE A TO INDEPENDENT AUDITOR'S REPORT OF EVEN DATE ON THE FINANCIAL STATEMENTS

Referred to in paragraph 1 under the heading "Report on Other Legal & Regulatory Requirements" of our report even date to the members of MVL Medisynth Private Limited on the financial statements for the year ended March 31, 2021:

- i. In respect of its fixed assets:
  - (a) The company is maintained proper records showing full particulars, including quantitative details and details about the situation of fixed assets.
  - (b) As explained to us, the Company has physically verified assets, in accordance with a phased program of verification, which in our opinion is reasonable having regard to the size of the company and the nature of its assets. No material discrepancies were noticed on such physical verification as compared with the available records.
  - (c) According to the information and explanations given to us and on the basis of our examination, the title deeds of immovable properties are held in the name of the Company.
- ii. In respect of its inventories:

As explained to us, inventories have been physically verified during the year by the management. In our opinion the frequency of verification is reasonable. Discrepancies noticed on physical verification of the inventories between the physical inventories and book records were not material, having regard to the size of the operations of the Company, and the same have been properly dealt with.
- iii. During the year, the Company has not granted any loans, secured or unsecured, to Companies, firms or other parties covered in the register maintained under Section 189 of the Companies Act, 2013.
- iv. The Company has not given any loan, made investments and provided guarantees and securities during the year. Therefore, the provisions of the clause (iv) of paragraph 3 of the Order are not applicable to the Company.
- v. According to the information and explanations given to us, the Company has not accepted any deposits from the public. Therefore, the provisions of the clause (v) of paragraph 3 of the Order are not applicable to the Company.
- vi. According to the information and explanations given to us, Central Government has not prescribed maintenance of cost records under sub-Section (1) of Section 148 of the Act in respect of activities carried on by the Company. Therefore, the provisions of clause (vi) of paragraph 3 of the Order are not applicable to the Company.



- vii According to the information and explanations given to us, in respect of statutory dues:
- (a) The Company has generally been regular in depositing undisputed statutory dues, including Provident Fund, Income tax, Sales tax, Service tax, Customs Duty, Excise Duty, Value Added Tax or Goods and Service Tax, Cess and any other statutory dues with the appropriate authorities. According to the information and explanations given to us, no undisputed amounts payable in respect of such statutory dues were outstanding as at March 31, 2021 for a period of more than six months from the date they became payable.
  - (b) According to information and explanations given to us, there are no dues of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax or Goods and Service Tax as applicable, which have not been deposited on account of any dispute.
- viii. Based on our audit procedure and according to the information and explanations given by the management, we are of the opinion that as on 31<sup>st</sup> March, 2021 the Company has not defaulted in repayment of dues to banks and financial institutions. The Company does not have any borrowings from Government and debenture holders.
- ix. According to the information and explanations given to us, during the year the Company has not raised any money by way of initial public offer, further public offer. The term loans raised during the year is utilized for the purpose for which they were raised.
- x. Based on our audit procedures performed for the purpose of reporting the true and fair view of the financial statements and on the basis of information and explanations given by the management, no fraud by the Company or on the Company by its officers or employees has been noticed or reported during the year.
- xi. The company has not paid or provided managerial remuneration.
- xii. In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause (xii) of paragraph 3 of the Order and not applicable to the Company.
- xiii According to the information and explanations given to us, Companies' transactions with the related parties are in compliance with section 177 and 188 of the Act as applicable and details of such transactions have been disclosed in the financial statements as required by the applicable Indian accounting standards.
- xiv According to the information and explanations give to us and based on our examination of the records of the Company, during the year, the Company has not raised money by private placement of share and provision of section 42 of the Companies Act 2013 has been complied with.



- xv According to the information and explanations given to us, during the year the Company has not entered into any non-cash transactions with directors or persons connected with him, therefore, the provisions of clause (xv) of paragraph 3 of the Order are not applicable to the Company.
- xvi In our opinion and according to information and explanations provided to us, the Company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

**DATE: 02/09/2021.**

**PLACE: SOLAPUR.**

**FOR AHERKAR & CO.,  
CHARTERED ACCOUNTANTS.  
F.R.No. 100170W**

  
**( C.A. S. P. Jawalkar )**

**Proprietor.**

**M.No. 130176.**

**UDIN-21130176AAAAIJ4503**





**“ANNEXURE B” TO THE INDEPENDENT AUDITOR’S REPORT (Referred to in paragraph 2(f) under ‘Report on Other Legal and Regulatory Requirements’ section of our report to the Members of MVL MEDISYNTH PRIVATE LIMITED, SOLAPUR**

Report on the Internal Financial Controls Over Financial Reporting under clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of MVL MEDISYNTH PRIVATE LIMITED (“the Company”), Solapur as of March 31, 2021 in conjunction with our audit of the Standalone financial statements of the Company for the year ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence of respective Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditor’s Responsibility**

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and it such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.



We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the company.

### **Meaning of Internal Financial Controls over Financial Reporting**

A Company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

### **Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were commensurate with the nature of the business of the unit and operating effectively as at March 31, 2021, based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

DATE: 02/09/2021.

PLACE: SOLAPUR.

**FOR AHERKAR AND CO.,  
CHARTERED ACCOUNTANTS  
F.R.No. 100170W**

( CA S. P. Jawalkar )

Proprietor.

M.No. 130176.

UDIN-21130176AAAAIJ4503



**MVL Medisynth Private Limited**  
**Balance Sheet As At March 31, 2021**

( Rupees )

Particulars	Note No.	As at March 31, 2021	As at March 31, 2020
<b>ASSETS</b>			
<b>1. Non - current assets</b>			
a. Property, plant and equipment	2	27,42,26,809	27,60,94,828
b. Capital work - in -progress	3	-	-
c. Investment Property		-	-
d. Goodwill		-	-
e. Other Intangible assets		-	-
f. Intangible assets under development		-	-
g. Biological Assets other than bearer plants		-	-
h. Financial Assets		-	-
(i) Investments		-	-
(ii) Trade Receivables		-	-
(iii) Loans		-	-
(iv) Others (to be specified)	4	17,87,487	18,11,487
i. Deferred tax assets (net)		-	-
j. Other non-current assets	5	1,59,832	7,91,913
<b>Total Non - current assets</b>		<b>27,61,74,128</b>	<b>27,86,98,228</b>
<b>2. Current assets</b>			
(a) Inventories	6	2,18,90,153	65,72,803
(b) Financial Assets		-	-
(i) Investments		-	-
(ii) Trade Receivables	7	3,09,13,884	22,26,176
(iii) Cash and cash equivalents	8	9,232	3,212
(iv) Bank balances other than (iii) above	9	7,13,818	6,69,464
(v) Loans		-	-
(vi) Others (to be specified)		-	-
(c) Current Tax Assets (Net)		17,021	18,118
(d) Other current assets	10	3,34,69,415	3,65,18,652
<b>Total Current assets</b>		<b>8,70,13,523</b>	<b>4,60,08,425</b>
<b>Total Assets</b>		<b>36,31,87,651</b>	<b>32,47,06,653</b>

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**




**MVL Medisynth Private Limited**  
**Balance Sheet As At March 31, 2021**


( Rupees )

Particulars	Note No.	As at March 31, 2021	As at March 31, 2020
<b>EQUITY AND LIABILITIES</b>			
<b>EQUITY</b>			
(a) Equity Share capital	11	4,50,00,000	4,50,00,000
(b) Other Equity			
(i) Reserves and surplus	12	-1,12,237	-1,37,932
<b>Total Equity</b>		<b>4,48,87,763</b>	<b>4,48,62,068</b>
<b>LIABILITIES</b>			
<b>1. Non - current liabilities</b>			
<b>(a) Financial Liabilities</b>			
(i) Borrowings	13	25,14,21,839	22,52,74,243
(ii) Trade payables	14	19,85,377	1,12,16,854
(iii) Other financial liabilities (other than those specified in item (b), to be specified)		-	-
<b>(b) Provisions</b>			
(c) Deferred tax liabilities (Net)	15	1,69,374	1,56,655
(d) Other non-current liabilities		-	-
<b>Total Non - current liabilities</b>		<b>25,35,76,590</b>	<b>23,66,47,752</b>
<b>2. Current liabilities</b>			
<b>(a) Financial Liabilities</b>			
(i) Borrowings	16	-52,32,426	91,46,252
(ii) Trade payables	17	3,84,26,129	25,33,487
(iii) Other financial liabilities (other than those specified in item (c))	18	3,00,81,598	3,03,51,938
<b>(b) Other current liabilities</b>			
(c) Provisions	19	7,515	39,644
(d) Current Tax Liabilities (Net)	20	14,33,482	10,40,512
	21	7,000	85,000
<b>Total Current liabilities</b>		<b>6,47,23,298</b>	<b>4,31,96,833</b>
<b>Total Liabilities</b>		<b>31,82,99,888</b>	<b>27,98,44,585</b>
<b>Total Equity and Liabilities</b>		<b>36,31,87,651</b>	<b>32,47,06,653</b>
Significant Accounting Policies and other disclosures	1		

For MVL Medisynth Private Limited

  
N.Eeshan Reddy  
Director

Place : Solapur  
Date : 02/09/2021


  
G.Tanmai Reddy  
Director

SUBJECT TO OUR REPORT OF EVEN DATE

For Aherkar & Co.

Chartered Accountants

F.R.No.100170W

  
CA S.P. Jawalkar

Proprieter

M.No.130176

UDIN : 21130176AAAAIJ4503





**MVL Medisynth Private Limited**  
**Statement of Profit And Loss For The Period Ended March 31, 2021**

( Rupees )

Particulars	Note No.	For the Period ended March 31, 2021	For the Period ended March 31, 2020
I Revenue from operations	22	13,03,12,592	5,95,42,062
II Other income	23	1,05,047	1,04,024
<b>III Total Revenue (I+II)</b>		<b>13,04,17,639</b>	<b>5,96,46,086</b>
<b>IV EXPENSES</b>			
Cost of Material Consumed	24	8,84,08,338	5,99,78,820
Changes in inventories of finished goods and work-in-progress	25	-105,57,865	-47,75,461
Employee benefits expense	26	51,06,534	2,72,090
Finance costs	27	1,52,57,583	7,81,163
Depreciation and amortization expense	2	1,14,22,102	5,28,083
Other expenses	28	2,07,37,268	23,23,429
<b>Total Expenses (IV)</b>		<b>13,03,73,959</b>	<b>5,91,08,123</b>
<b>V Profit/(loss) before exceptional items and tax (III - IV)</b>		<b>43,680</b>	<b>5,37,963</b>
<b>VI Exceptional items</b>			
<b>VII Profit/(loss) before tax (V - VI)</b>		<b>43,680</b>	<b>5,37,963</b>
<b>VIII Tax Expenses:</b>			
1. Current Tax		7,000	85,000
2. Deferred Tax		12,719	1,56,655
3. Adjustments of earlier year tax provisions		-1,735	-
<b>IX Profit (Loss) for the period from continuing operations (VII-VIII)</b>		<b>25,695</b>	<b>2,96,308</b>
<b>X Profit/(loss) from discontinued operations</b>		-	-
<b>XI Tax expense of discontinued operations</b>		-	-
<b>XII Profit/(loss) from discontinued operations (after tax) (X-XI)</b>		-	-
<b>XIII Profit /Loss for the period (IX + XII)</b>		<b>25,695</b>	<b>2,96,308</b>
<b>XIV Other Comprehensive Income</b>			
A (i) Items that will not be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-
B (i) Items that will be reclassified to profit or loss		-	-
(ii) Income tax relating to items that will be reclassified to profit or loss		-	-
<b>XV Total Comprehensive Income for the period ( XIII + XIV) (Comprising profit/loss and other Comprehensive Income for the period)</b>		<b>25,695</b>	<b>2,96,308</b>
<b>XVI Earning per equity share (for continuing operation):</b>			
(1) Basic		0.01	0.07
(2) Diluted		0.01	0.07
<b>XVII Earning per equity share (for discontinued operation):</b>			
(1) Basic		-	-
(2) Diluted		-	-
<b>XVIII Earning per equity share (for discontinued &amp; continuing operations)</b>			
(1) Basic		0.01	0.07
(2) Diluted		0.01	0.07
Significant Accounting Policies and other disclosures	1		

For MVL Medisynth Private Limited


  
N. Eeshan Reddy  
Director

  
G. Tanmai Reddy  
Director

Place : Solapur  
Date : 02/09/2021

SUBJECT TO OUR REPORT OF EVEN DATE

For Aherkar & Co.  
Chartered Accountants  
F.R.No.109170W

  
S.P. Jawalkar  
Proprietor  
M.No.130176

UDIN : 21130176AAAAIJ4503



**NOTE 1**

**NOTES FORMING PART OF FINAL ACCOUNTS FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2021:**

**1. BASIS OF PREPARATION:**

The financial statements of the Company have been prepared in accordance with Indian Accounting Standards notified under the Companies (Indian Accounting Standards) Rules 2015 (Ind AS).

For all period up to year ended 31<sup>st</sup> March, 2021, the Company prepared its financial statements in accordance with accounting standards notified under the Section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules, 2014 (Indian GAAP). These financial statements for the year ended 31<sup>st</sup> March, 2021 are the first financial statement, the Company has prepared in accordance with Ind AS.

The financial statements have been prepared on a historical cost basis, except for certain financial assets and liabilities, which are measured at fair value / amortised cost.

The financial statements are prepared in Indian Rupees (Rs.), which is the Company's functional and presentation currency and all values are rounded to the nearest rupees except when otherwise indicated.

**2. FIXED ASSETS:**

Fixed assets are stated at cost of acquisition or construction less accumulated depreciation. All costs relating to the acquisition & installation of fixed assets are capitalized.

**3. DEPRECIATION:**

Depreciation has been provided as under:

- a) For assets existing on 1<sup>st</sup> April, 2020 the carrying amount will be amortised over the remaining useful lives on straight line method as prescribed in the Schedule II of the Companies Act, 2013.
- b) For the assets added after the 1<sup>st</sup> April, 2020
  - i) On All Assets - On Straight Line Method at the useful lives prescribed in Schedule II of the Companies Act, 2013

**4. INVESTMENTS:**

The company does not hold any investments.

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**



5. **REVENUE RECOGNITION:**

In respect of sale of product and services, revenue is recognized when the goods are dispatched and services are rendered.

6. **DEPOSITS:**

The deposits have been shown at cost plus accrued interest, wherever applicable upto the date of Balance Sheet.

7. **TAXATION:**

- i) Current Tax is determined as the amount of tax payable in respect of taxable income for the year.
- ii) Deferred Tax resulting from timing differences between taxable profits and book profits are accounted for using the tax rates and laws that have been enacted or substantially enacted as of the Balance Sheet date. However, in case of deferred tax assets are recognized to the extent there is virtual certainty that there would be adequate future taxable income against which such deferred tax assets can be realised.

8. **IMPAIRMENT OF ASSETS:**

The company has not estimated recoverable amount of the asset as prescribed in AS-28, as the company has not followed AS-28.

9. **DEFERRED TAX:**

- a) Deferred tax has been provided in accordance with Accounting Standard –22, Accounting for taxes on income issued by the Institute of Chartered Accountants of India applicable from 1<sup>st</sup> April, 2002.
- b) The breakup of net deferred tax liability as on 31<sup>st</sup> March, 2021 is as under-

	Deferred Tax Liability Rs.	Deferred Tax Asset Rs.
Difference between book & tax W.D.V. Company W.D.V. 27,04,94,649 I.T. W.D.V. 19,05,16,615 ----- Difference 7,99,78,034@ 29.12%	2,32,89,603	--
Net Deferred Tax Liability	2,32,89,603	

Opening Deferred Tax Liability 1,09,27,684  
Current year Deferred Tax Liability 1,23,61,919  
-----  
Net Deferred Tax Liability Shown in Balance Sheet 2,32,89,603  
-----

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**

...4.



Particulars	Income Add Dep. ITR @ 29.12%
Loss as per Companies Act	0
As per IT Act there would be no tax on the loss & loss would be carried forward F..Y. 2020-21	7,93,96,392
Total	-7,93,96,392
Deferred Tax Asset @ 29.12%	-2,31,20,229
Less: Deferred Tax Asset as on 31.03.2020	-1,07,71,029
Deferred Tax Asset as on date	-1,23,49,200
Net Deferred Tax Assets as on date	12,719

10. **EXTRA ORDINARY ITEMS:**

The Profit & Loss Account does not include any extra ordinary item of non-recurring nature.

11. **OTHER ACCOUNTING POLICIES:**

The Company follows generally accepted accounting principles in respect of accounting policies not specifically referred to hereinabove.

12. **MISCELLANEOUS:**

- a) All the accounts of Debtors and Creditors are subject to confirmation.
- b) Previous year's figures are regrouped wherever necessary.


FOR MVL MEDISYNTH PVT. LTD.

  
DIRECTOR

  
DIRECTOR

DATE: 02/09/2021.  
PLACE: SOLAPUR.

FOR AHERKAR & CO.,  
CHARTERED ACCOUNTANTS  
F.R.No. 100170W

  
( CA S.P. Jawalkar )  
Proprietor.  
M.No. 130176.  
UDIN-21130176AAAAIJ4503





MVL MEDISYNTH PRIVATE LIMITED  
 Note 2 : Property, plant and equipment

(Rupees)

Assets	GROSS BLOCK			DEPRECIATION			NET BLOCK			
	As at 31.03.2020	Additions	Deletion	As at 31.03.2021	As at 31.03.2020	For the Period	Deletion	As at 31.03.2021	As at 31.03.2020	As at 31.03.2021
Land & Site Development	37,32,160			37,32,160	0	0			37,32,160	37,32,160
Factory Buildings	5,41,34,912		5,00,000	5,36,34,912	79,843	16,94,944		17,74,787	5,40,55,069	5,18,60,125
Plant & Machinery	18,34,25,598	1,00,02,471		19,34,28,069	3,81,923	83,02,173		86,84,096	18,30,43,675	18,47,43,973
Plant & Machinery - Boiler	1,12,63,609	28,800		1,12,92,409	19,935	4,29,111		4,49,046	1,12,43,674	1,08,43,363
Fire Hydrant System	7,97,817			7,97,817	1,412	30,317		31,729	7,96,405	7,66,088
Thermic Fluid Heater	1,42,61,947			1,42,61,947	25,242	5,41,954		5,67,196	1,42,36,705	1,36,94,751
Laboratory Equipment	13,19,328			13,19,328	5,838	1,25,336		1,31,174	13,13,490	11,88,154
Computer	17,288			17,288	255	5,475		5,730	17,033	11,558
Furniture	22,449			22,449	99	2,133		2,232	22,350	20,217
Air Conditioner		22,812		22,812	0	42		42	0	22,770
Effluent Treatment Equipments	76,47,803			76,47,803	13,536	2,90,617		3,04,153	76,34,267	73,43,650
<b>Total</b>	<b>27,66,22,911</b>	<b>1,00,54,083</b>	<b>5,00,000</b>	<b>28,61,76,994</b>	<b>5,28,083</b>	<b>1,14,22,102</b>	<b>0</b>	<b>1,19,50,185</b>	<b>27,60,94,828</b>	<b>27,42,26,809</b>

MVL MEDISYNTH PVT. LTD.  
 DIRECTOR



**MVL Medisynth Private Limited**  
Notes forming part of the Financial Statements

( Rupees )

Particulars	As at March 31, 2021	As at March 31, 2020
<b>Note 3 : Capital Work in Progress</b>	-	-
<b>Note 4 : Others</b>		
Deposit with Government Departments	17,85,787	17,85,787
Others-Security Deposits	1,700	25,700
<b>Total</b>	<b>17,87,487</b>	<b>18,11,487</b>
<b>Note 5 : Other non-current assets</b>		
Capital advances recoverable within one year	41,284	6,43,728
Preliminary Exps.	1,18,548	1,48,185
<b>Total</b>	<b>1,59,832</b>	<b>7,91,913</b>
<b>Note 6 : Inventories</b> [As verified, valued and certified by the Management]		
Raw Material	31,01,983	8,34,864
Finished Goods	1,32,82,170	48,77,000
Goods-in-transit / at Bonded Warehouse	15,77,961	-
Work-in-Process	21,52,695	-
Packing Materials	7,47,530	3,61,051
Fuel & Others etc.	7,73,303	4,99,888
Stores & Spares	2,54,511	-
<b>Total</b>	<b>2,18,90,153</b>	<b>65,72,803</b>
<b>Note 7 : Trade Receivables</b> (Unsecured and considered good)		
Trade Receivables	3,09,13,884	22,26,176
<b>Total</b>	<b>3,09,13,884</b>	<b>22,26,176</b>
<b>Note 8 : Cash and cash equivalents</b>		
Cash in hand	9,232	3,212
<b>Total</b>	<b>9,232</b>	<b>3,212</b>
<b>Note 9 : Bank balance other than above</b>		
<b>Balance with Scheduled Banks</b>		
In Current Accounts	15,541	8,154
In Margin money deposits (towards margin bank guarantees issued by banks.)	6,98,277	6,61,310
<b>Total</b>	<b>7,13,818</b>	<b>6,69,464</b>
<b>Note 10 : Other current Assets</b>		
Balance with Revenue Authorities	3,28,81,524	3,61,91,333
Advances to Suppliers	4,46,428	3,27,319
Others - Unsecured, considered good	1,41,463	-
<b>Total</b>	<b>3,34,69,415</b>	<b>3,65,18,652</b>

**MVL MEDISYNTH PVT. LTD.**

  
DIRECTOR



Particulars	As at March 31, 2021	As at March 31, 2020
<b>Note 11 : Equity share capital</b>		
<b>a. Authorised</b>		
1,00,00,000 Equity Shares of Rupees 10/- each	10,00,00,000	10,00,00,000
	<b>10,00,00,000</b>	<b>10,00,00,000</b>
<b>b. Issued, subscribed &amp; paid up</b>		
45,00,000 Equity Shares of Rs. 10/- each fully paid up	4,50,00,000	4,50,00,000
	<b>4,50,00,000</b>	<b>4,50,00,000</b>
<b>c. Par value of shares</b>	10/-	10/-
<b>d. Number of Share outstanding at the beginning of the year</b>	45,00,000	8,58,018
Changes during the year	0	36,41,982
Number of Shares outstanding at the end of the year	45,00,000	45,00,000
e. During the five years immediately preceding the current financial year, the company has not issued any shares without payment being received in cash, nor issued any bonus shares. Neither did the company buy back any shares during the said period.		
<b>f. Details of shareholders holding more than 5% share of the company</b>	<b>No. of Shares</b>	<b>Percentage %</b>
<b>Sl. No. Name of the Shareholder</b>	<b>Current Year</b>	<b>Previous Year</b>
	<b>Current Year</b>	<b>Previous Year</b>
1. N. Eeshan Reddy	12,37,736	12,37,736
2. G. Tanmai Reddy	8,17,105	8,17,105
3. N.Neha Reddy	5,25,031	5,25,031
4. D.Ram Reddy	4,73,644	4,73,644
5. Kalakota Sharath Reddy	4,50,001	4,50,001
6. G.Shritha Reddy	3,40,902	3,40,902
7. D.Vandana Reddy	3,14,679	3,14,679
8. N.Rajeshwar Reddy	2,62,232	2,62,232
<b>Note 12 : Other Equity - Reserves and Surplus</b>		
A) Share Premium Account	61,01,820	61,01,820
<b>Total A</b>	<b>61,01,820</b>	<b>61,01,820</b>
B) Balance in Statement of Profit and Loss brought forward from previous year	-62,39,752	-65,36,060
Add : Profit for the year	25,695	2,96,308
<b>Balance in Statement of Profit &amp; Loss at the end of year Total C</b>	<b>-62,14,057</b>	<b>-62,39,752</b>
<b>Total other equity (A + B + C)</b>	<b>-1,12,237</b>	<b>-1,37,932</b>
<b>Note 13 : Borrowings</b>		
<b>1. Secured - Term loans</b>		
(i) HDFC Bank Ltd	10,85,71,839	10,24,24,243

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**



Particulars	As at March 31, 2021	As at March 31, 2020
<b>2. Unsecured</b>		
<b>From Related Parties</b>		
(i) D. Tanmai Reddy	21,50,000	21,50,000
(ii) D. Ram Reddy	5,07,75,000	4,07,75,000
(iii) D. Vandana Reddy	1,48,25,000	1,48,25,000
(iv) Harshavardhan Reddy	19,00,000	19,00,000
(v) K. Himaja Reddy	29,50,000	29,50,000
(vi) N Eeshan Reddy	1,32,50,000	1,32,50,000
(vii) N. Rajeshwar Reddy	5,45,00,000	4,45,00,000
(viii) K. Sharath Reddy	25,00,000	25,00,000
<b>Total</b>	<b>25,14,21,839</b>	<b>22,52,74,243</b>
<b>Note 14 : Trade payables</b>		
Creditors for Capital Goods	19,85,377	1,12,16,854
Others	-	-
<b>Total</b>	<b>19,85,377</b>	<b>1,12,16,854</b>
<b>NOTE 15: Deferred Tax Liabilities / Assets</b>		
Beginning of the year relating to the fixed assets	1,56,655	-
<b>Total</b>	<b>1,56,655</b>	<b>-</b>
Add / (Less): Timing difference arising during the year on account of depreciation	12,719	1,56,655
<b>Deferred Tax Liability (Net)</b>	<b>1,69,374</b>	<b>1,56,655</b>
<b>Note 16 : Borrowings</b>		
<b>a. Secured</b>		
<b>Towards working capital - Repayable on demand</b>		
(i) HDFC Bank	-52,32,426	91,46,252
<b>Total</b>	<b>-52,32,426</b>	<b>91,46,252</b>
<b>Note 17 : Trade payables</b>		
Creditors for Raw Materials	3,84,26,129	25,33,487
<b>Total</b>	<b>3,84,26,129</b>	<b>25,33,487</b>
<b>Note 18 : Other financial liabilities</b>		
(a) Current maturities of long term debt from banks payable within twelve months	2,36,36,364	2,36,36,364
(b) Interest accrued and due on borrowings	10,37,716	11,13,119
(c) Other payables	53,72,859	55,74,294
(d) Advance from Customers	34,659	28,161
<b>Total</b>	<b>3,00,81,598</b>	<b>3,03,51,938</b>

**MVL MEDISYNTH PVT. LTD.**

*[Signature]*  
**DIRECTOR**



Particulars	As at March 31, 2021	As at March 31, 2020
<b>Note 19 : Other current liabilities</b>		
(a) Statutory remittances:		
Goods & Service Tax	-	-
Tax Deducted at Source	3,190	37,644
Professional Tax	4,325	2,000
<b>Total</b>	<b>7,515</b>	<b>39,644</b>
<b>Note 20 : Provisions</b>		
(a) Provision for employee benefits:		
Salaries	6,36,763	2,14,341
(b) Provision – Others		
Electricity Charges	6,53,006	7,28,442
Provident Fund	67,993	-
Employee State Insurance	18,572	-
Others	57,148	97,729
<b>Total</b>	<b>14,33,482</b>	<b>10,40,512</b>
<b>Note 21 : Current Tax Liabilities</b>		
Provision for Current Tax	7,000	85,000
<b>Total</b>	<b>7,000</b>	<b>85,000</b>

**MVL MEDISYNTH PVT. LTD.**

*α*  
  
**DIRECTOR**



**MVL Medisynth Private Limited**  
**Notes forming part of the Financial Statements**

( Rupees )

Particulars	For the Period ended March 31, 2021	For the Period ended March 31, 2020
<b>Note 22 : Revenue From Operations</b>		
Sales - Tradings	1,57,67,088	5,95,42,062
Sales - Manufacturing	11,45,45,504	-
<b>Total Revenue from operations ( Net )</b>	<b>13,03,12,592</b>	<b>5,95,42,062</b>
<b>Note 23 : Other Income</b>		
Interest on Fixed Deposit	25,455	31,027
Interest on Security Deposit	79,592	72,997
Other Income	-	-
<b>Total</b>	<b>1,05,047</b>	<b>1,04,024</b>
<b>Note 24 : Cost of material consumed</b>		
Opening Stock	8,34,864	-
Add: Purchases		
<b>Raw Material - Domestic</b>	<b>8,06,77,262</b>	<b>1,90,37,665</b>
Manufacturing	7,31,94,633	1,30,55,665
Trading	74,82,629	59,82,000
<b>Raw Material - Import</b>	<b>99,98,194</b>	<b>4,17,76,019</b>
Manufacturing	34,65,550	-
Trading	65,32,644	4,17,76,019
<b>Sub- Total</b>	<b>9,15,10,321</b>	<b>6,08,13,684</b>
Less : Closing Stock	31,01,983	8,34,864
<b>Net Total</b>	<b>8,84,08,338</b>	<b>5,99,78,820</b>
<b>Note 25 : Changes in Inventories of Finished Goods &amp; Work in Process</b>		
<b>(a) Opening Stock</b>		
Finished Goods	48,77,000	1,01,539
Work-in -process		-
<b>Sub- Total (a)</b>	<b>48,77,000</b>	<b>1,01,539</b>
<b>(b) Closing Stock</b>		
Finished Goods	1,32,82,170	48,77,000
Work-in -process	21,52,695	-
<b>Sub- Total (b)</b>	<b>1,54,34,865</b>	<b>48,77,000</b>
<b>Difference of (a) and (b) Increase (-) / Decrease(+)</b>	<b>-1,05,57,865</b>	<b>-47,75,461</b>

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**



Notes forming part of the Financial Statements

( Rupees )

Particulars	For the Period ended March 31, 2021	For the Period ended March 31, 2020
<b>Note 26 : Employee benefits</b>		
Salaries, Wages and other allowances	45,88,739	2,13,149
Provident Fund	3,06,049	-
Employee State Insurance	83,095	-
Labour Welfare Fund	756	-
Staff Welfare Expenses	1,22,863	-
Group Insurance Premium	5,032	58,941
<b>Total</b>	<b>51,06,534</b>	<b>2,72,090</b>
<b>Note 27 : Finance Cost</b>		
Interest on Working Capital Borrowings	16,30,049	2,06,615
Interest on Term loan	1,34,78,017	5,74,513
Bank Charges	77,800	35
Processing Fees	71,717	-
<b>Total</b>	<b>1,52,57,583</b>	<b>7,81,163</b>
<b>Note 28: Other Expenses</b>		
<b>a) Manufacturing Expenses</b>		
i) Power and Fuel	1,39,42,822	18,91,033
ii) Stores & Spares	8,11,949	-
iii) Repairs & Maintenance - Plant & Machinery	3,54,990	-
iv) Repairs & Maintenance - Building & Other	3,806	-
<b>b) Selling &amp; Distribution Expenses</b>		
i) Advertisement, Publicity & Sales Promotion	12,420	-
ii) Discount on Sales	-	6,300
iii) Outward Freight	19,72,570	1,97,612
iv) Packing & Forwarding	25,20,292	5,439
v) Other Selling & Distribution	-	1,76,580
<b>c) Administrative &amp; General Expenses</b>		
i) Foreign Exchange Fluctuations Loss / (Gain)	-90,975	-
ii) Rates & Taxes	8,04,178	1,300
iii) Other Expenses	2,205	39,129
iv) Preliminary Expenses written off	29,637	-
<b>d) Insurance</b>		
i) Raw Material & Finished Goods	73,166	6,036
ii) Plant & Machinery Building	3,00,208	-
<b>Total</b>	<b>2,07,37,268</b>	<b>23,23,429</b>

**MVL MEDISYNTH PVT. LTD.**

  
DIRECTOR



**MVL Medisynth Private Limited**  
**Balance Sheet - Sub-Notes As at 31.03.2021**

<b>A. Term Loan From Banks - Secured</b>		(Rupees)
Particulars	As at March 31, 2021	
HDFC Bank Ltd. - Term Loan – 007LN06190280001	1,24,57,087	
HDFC Bank Ltd. - Term Loan – 007LN06190660001	31,14,272	
HDFC Bank Ltd. - Term Loan – 007LN06190790002	93,42,815	
HDFC Bank Ltd. - Term Loan – 007LN06190840002	80,97,107	
HDFC Bank Ltd. - Term Loan – 007LN06190900005	31,14,272	
HDFC Bank Ltd. - Term Loan – 007LN06190990001	1,24,57,087	
HDFC Bank Ltd. - Term Loan – 007LN06191160001	40,48,553	
HDFC Bank Ltd. - Term Loan – 007LN06191270002	62,28,544	
HDFC Bank Ltd. - Term Loan – 007LN06191360001	62,28,544	
HDFC Bank Ltd. - Term Loan – 007LN06191430002	93,43,588	
HDFC Bank Ltd. - Term Loan – 007LN06191500004	62,28,544	
HDFC Bank Ltd. - Term Loan – 007LN06191640001	3,11,427	
HDFC Bank Ltd. - Term Loan – 2407LN65202260001 (Covid)	2,76,00,000	
<b>Total</b>	<b>10,85,71,839</b>	

**B. Working Capital - Loans Repayable on Demand**

Particulars	As at March 31, 2021
HDFC Bank Ltd.	-52,32,426
<b>Total</b>	<b>-52,32,426</b>

**L. Packing Material**

Particulars	As at March 31, 2021
HDFC Bank Ltd. - Term Loan – 007LN06190280001	1,29,896
HDFC Bank Ltd. - Term Loan – 007LN06190660001	32,474
HDFC Bank Ltd. - Term Loan – 007LN06190790002	97,422
HDFC Bank Ltd. - Term Loan – 007LN06190840002	84,432
HDFC Bank Ltd. - Term Loan – 007LN06190900005	32,474
HDFC Bank Ltd. - Term Loan – 007LN06190990001	1,29,896
HDFC Bank Ltd. - Term Loan – 007LN06191160001	42,216
HDFC Bank Ltd. - Term Loan – 007LN06191270002	64,948
M. Salaries, Wages & other allowances	64,948
HDFC Bank Ltd. - Term Loan – 007LN06191430002	97,428
HDFC Bank Ltd. - Term Loan – 007LN06191500004	64,948
HDFC Bank Ltd. - Term Loan – 007LN06191640001	3,247
HDFC Bank Ltd. - Term Loan – 2407LN65202260001 (Covid)	1,93,389
<b>Total</b>	<b>10,37,716</b>

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**





**MVL Medisynth Private Limited**  
**Balance Sheet - Sub-Notes As at 31.03.2021**

**D. Deposits with Government Departments**

Particulars	As at March 31, 2021
State Electricity Board	15,45,488
MIDC Water Deposit	2,40,299
<b>Total</b>	<b>17,85,787</b>

**O. Advertisement, Publicity & Sales Promotion Expenses**

**E. Other Deposits**

Particulars	As at March 31, 2021
Cylinder Deposit	1,700
Security Deposit	
<b>Total</b>	<b>1,700</b>

**F. Other - Short Term Loans & Advances**

Particulars	As at March 31, 2021
P. Other Expenses	1,41,463
<b>Total</b>	<b>1,41,463</b>

**F. Balance with Revenue Authorities**

Particulars	As at March 31, 2021
CGST Receivable	1,44,82,880
SGST Receivable	1,80,31,075
IGST Receivable	49
IGST Refund Receivable on Export	2,95,099
Interest Receivable	72,421
<b>Total</b>	<b>3,28,81,524</b>

**G. Other Payables - Employees**

Particulars	As at March 31, 2021
Salaries	6,36,763
<b>Total</b>	<b>6,36,763</b>

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**



**MVL Medisynth Private Limited**  
**Balance Sheet - Sub-Notes As at 31.03.2021**

**Q. Other Selling & Distribution Expenses**

Particulars	As at March 31, 2021
Provision of Taxation	
Provision – Others	
Audit Fees	
Carriage Outward	17,317
Water Charges	39,831
<b>Total</b>	<b>57,148</b>

**I. Other Payables**

Particulars	As at March 31, 2021
<b>Deposits:</b>	
M/s. Oswal Chem (India) Pvt. Ltd.	51,37,359
<b>Security Deposits:</b>	
Tejashri Construction	2,35,500
<b>Total</b>	<b>53,72,859</b>

**MVL MEDISYNTH PVT. LTD.**

  
**DIRECTOR**



**MVL MEDISYNTH PRIVATE LIMITED**

**Profit and Loss - Sub-Notes for the year ended 31.03.2021**

**J. Power & Fuel Consumed** (Rupees)

Particulars	For the Period ended March 31, 2021
Opening Stock	4,99,888
Add :	
Electricity Charges - Factory	79,47,251
Purchase of Coal	62,68,986
Sub - Total : A	<b>1,47,16,125</b>
Closing Stock	7,73,303
Sub - Total : B	<b>7,73,303</b>
Net Total :(A - B)	<b>1,39,42,822</b>

**K. Purchase Stores & Spares**

Particulars	For the Period ended March 31, 2021
Opening Stock	
Add : Purchases	10,66,460
Sub - Total : A	<b>10,66,460</b>
Less :	
Closing Stock	2,54,511
Sub - Total : B	<b>2,54,511</b>
Net Total : A- B	<b>8,11,949</b>

**L. Packing Material**

Particulars	For the Period ended March 31, 2021
Opening Stock	3,61,051
Add : Purchases	29,06,771
Sub - Total : A	<b>32,67,822</b>
Less :	
Closing Stock	7,47,530
Sub - Total : B	<b>7,47,530</b>
Net Total : A- B	<b>25,20,292</b>

**MVL MEDISYNTH PVT. LTD.**

*(Signature)*  
**DIRECTOR**



**M. Salaries, Wages & other allowances**

Particulars	For the Period ended March 31, 2021
Aminities to Factory Staff	2,250
Salary to Office Staff	1,84,200
Salaries - Production Staff	44,02,289
<b>Total</b>	<b>45,88,739</b>

**N. Rates & Taxes**

Particulars	For the Period ended March 31, 2021
Professional Tax	10,000
Rent Rates	90,059
Registration & Renewals	1,86,119
Stamp Duty	5,18,000
<b>Total</b>	<b>8,04,178</b>

**O. Advertisement, Publicity & Sales Promotion Expenses**

Particulars	For the Period ended March 31, 2021
Advertisement	
Commission to Sales Promoters	12,420
<b>Total</b>	<b>12,420</b>

**P. Other Expenses**

Particulars	For the Period ended March 31, 2021
Admin Charges - PF	26,207
General Office Exps.	2,000
Legal Charges	1,620
Printing & Stationary	22,468
Professional/Consultancy Charges	17,500
Safety Equipment Exps.	15,400
Filing Fees	11,724
GST Audit Fees	20,000
Audit Fees	30,000
Testing Charges	6,750
Travelling Exps Factory	4,675
Travelling Exps Office	4,793
TDS Expenses	88
Written Off Account	-1,61,020
<b>Total</b>	<b>2,205</b>

**MVL MEDISYNTH PVT. LTD.**

*[Signature]*  
DIRECTOR

